DHH1 Antibody

What is DHH1 and what cellular functions does it perform?

DHH1 is a highly conserved DEAD-box RNA helicase that plays crucial roles in mRNA decay and translational repression pathways. It consists of N- and C-terminal RecA-like domains connected by a short linker and binds RNA with high affinity in a sequence-independent manner through the phosphate backbone . DHH1 functions at an early step in processing body (P-body) formation, making it a key factor in facilitating mRNA inactivation . In yeast, DHH1 interacts with Not1, the central scaffold subunit of the CCR4-NOT deadenylase complex, through its MIF4G domain, and this interaction is evolutionary conserved between yeast and humans . DHH1 is an abundant protein with approximately 400,000 molecules per cell, which significantly exceeds the estimated 50,000 total mRNA molecules per cell in organisms like trypanosomes .

What are the recommended applications for DHH1 antibody?

DHH1 antibodies have been successfully employed in multiple experimental applications including:

• Western Blot (WB): Recommended dilution ranges from 1:500 to 1:2000, though optimal concentration should be determined empirically for each specific application and sample type .

• Immunohistochemistry (IHC): Successfully used in published literature to visualize DHH1 protein in tissue sections .

• Immunofluorescence (IF): Effective for studying DHH1 localization, particularly for examining P-body formation and dynamics .

• Immunoprecipitation (IP): High-affinity antibodies have been used to isolate DHH1-GFP complexes for proteomic analysis, enabling the identification of novel interacting partners .

How should DHH1 antibody be stored to maintain optimal activity?

DHH1 antibodies typically should be stored at -20°C in aliquots to minimize freeze-thaw cycles. Commercial antibodies are often supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 to maintain stability . These storage conditions typically ensure the antibody remains stable for at least one year after shipment. For smaller volume antibodies (approximately 20μl), manufacturers often include 0.1% BSA as a stabilizer . Aliquoting is generally unnecessary for -20°C storage, but is recommended if repeated use is anticipated to prevent degradation from multiple freeze-thaw cycles.

What is the expected molecular weight of DHH1 in Western blot applications?

The calculated molecular weight of full-length DHH1 is approximately 44 kDa, with observed bands typically appearing around 42 kDa in Western blot applications . When interpreting Western blot results, researchers should be aware that post-translational modifications may cause slight variations in the observed molecular weight. Specific positive controls, such as mouse skeletal muscle tissue, have been validated for DHH1 antibody testing . When performing Western blot analysis, it is advisable to include both positive and negative controls to confirm specificity of the detected bands.

What methods are available for studying DHH1 localization in P-bodies?

Several approaches have been successfully employed to study DHH1 localization in P-bodies:

• Fluorescent protein tagging: eYFP-DHH1 fusions have been verified as fully functional and are commonly used to track DHH1 localization to P-bodies in live cells . Wild-type eYFP-DHH1 localizes to microscopically visible P-bodies in 100% of cells under appropriate conditions .

• Immunofluorescence: Anti-DHH1 antibodies can be used to visualize endogenous DHH1 in fixed cells. This approach is particularly useful when studying cells where genetic manipulation is challenging.

• Stress induction: P-body formation can be enhanced by treatments such as puromycin exposure or heat shock, which increase the microscopically visible localization of DHH1 .

• Co-localization studies: Using other P-body markers such as SCD6-eYFP alongside DHH1 antibody staining can confirm P-body identity and provide information about P-body composition under different conditions .

How can I validate the specificity of a DHH1 antibody?

Validating antibody specificity is crucial for reliable research outcomes. For DHH1 antibody, consider these validation approaches:

• Western blot analysis: Compare wild-type cells with DHH1 knockout or knockdown cells to confirm the absence of signal in cells lacking the target protein.

• Peptide competition assay: Pre-incubate the antibody with excess DHH1 immunizing peptide before application to verify signal reduction or elimination.

• Immunoprecipitation followed by mass spectrometry: This approach can confirm that the antibody is capturing the intended target protein along with known interacting partners.

• Cross-validation with multiple antibodies: Using antibodies raised against different epitopes of DHH1 should produce consistent localization patterns.

• Genetic tagging validation: Compare antibody staining patterns with the localization of fluorescently tagged DHH1 expressed from its endogenous locus.

How does ATP hydrolysis by DHH1 regulate P-body dynamics?

ATP hydrolysis is a critical regulatory mechanism controlling DHH1's function in P-body formation and dynamics. Mutations in the DEAD motif (E195Q, or DHH1 DQAD) that disrupt ATP hydrolysis lead to the formation of constitutive granules with both the behavior and composition of P-bodies even in the absence of stress .

The ATPase cycle of DHH1 acts as a key regulator of P-body nucleation and disassembly. In wild-type conditions, Not1 stimulates the ATPase activity of DHH1, similar to its function in mammals . Disruption of the interaction between DHH1 and Not1 in vivo results in the formation of P-bodies in the absence of stress, phenocopying the catalytically dead DHH1 DQAD allele .

In vitro experiments have demonstrated that DHH1, ATP, and RNA are sufficient to form liquid droplets, highlighting the direct role of DHH1's biochemical properties in phase separation phenomena underlying P-body formation . These findings collectively establish that the ATP-bound state of DHH1 promotes P-body assembly, while ATP hydrolysis drives disassembly and recycling.

What experimental approaches can be used to study the interaction between DHH1 and the CCR4-NOT complex?

The interaction between DHH1 and the CCR4-NOT complex, particularly through Not1, is crucial for modulating DHH1's activity. Several experimental approaches can be employed to investigate this interaction:

• Co-immunoprecipitation (Co-IP): Using antibodies against DHH1 to pull down protein complexes, followed by Western blotting for Not1 or other CCR4-NOT components. High-affinity antibodies have been successfully used to isolate DHH1-GFP complexes under conditions that preserve the P-body aggregate state .

• Yeast two-hybrid assays: This system can test direct protein-protein interactions and map interaction domains between DHH1 and Not1.

• In vitro binding assays: Recombinant proteins can be used to assess direct binding and determine binding kinetics and affinity constants.

• Mutational analysis: Introducing mutations in the interaction surfaces between DHH1 and Not1 can assess the functional importance of specific residues. For example, mutations that disrupt the interaction lead to P-body formation in the absence of stress, similar to catalytically inactive DHH1 .

• Proximity ligation assay (PLA): This technique can detect protein-protein interactions in situ, providing spatial information about where DHH1 and Not1 interact within the cell.

• Structural biology approaches: X-ray crystallography or cryo-EM studies of DHH1-Not1 complexes can reveal atomic-level details of the interaction interfaces.

How can researchers differentiate between DHH1's roles in mRNA decay versus translational repression?

DHH1 functions in both mRNA decay and translational repression, and distinguishing between these roles requires specific experimental approaches:

• Tethering assays: DHH1 or mutant variants can be tethered to reporter mRNAs to assess their effects on mRNA stability and translation. For example, tethering DHH1-PP7CP to FBA1 mRNA caused an 80% reduction in mRNA levels, while the DHH1 DQAD variant showed partial attenuation of mRNA decay (55% reduction) .

• Polysome profiling: This technique separates mRNAs based on their association with ribosomes. DHH1 overexpression or expression of catalytically inactive dhh1 mutants in T. brucei causes a decrease in polysomes, consistent with translational repression .

• Single-molecule mRNA fluorescence in situ hybridization (smFISH): This approach can track specific mRNAs and determine their colocalization with P-bodies. For instance, in glucose-starved cells expressing wild-type DHH1, only 11% of FBA1 mRNAs colocalized with P-body foci, whereas in xrn1Δ cells (defective in 5' to 3' mRNA decay), 75% colocalized with P-bodies .

• Ribosome profiling combined with RNA-Seq: This powerful approach can simultaneously measure changes in translation efficiency and mRNA abundance in cells with altered DHH1 activity. Studies in yeast have shown that Pat1 and DHH1 collaborate to reduce both translation and protein production from many mRNAs .

• Pulse-chase experiments: These can help determine the kinetics of mRNA decay in the presence or absence of functional DHH1.

What controls should be included when studying DHH1 mutants?

When investigating DHH1 mutants, appropriate controls are essential for reliable interpretation of results:

• Wild-type DHH1: Include wild-type DHH1 as a positive control to establish baseline activity and localization patterns. For example, wild-type eYFP-DHH1 localizes into microscopically visible P-bodies in 100% of cells, serving as a reference point for mutant behavior .

• Multiple mutant clones: Test multiple independent clones for each DHH1 mutant to ensure consistency and rule out clone-specific effects. Studies with T. brucei DHH1 mutants tested three independent clones for each transgene to confirm reproducibility of growth phenotypes .

• Expression level controls: Monitor expression levels of DHH1 mutants relative to endogenous DHH1, as even modest overexpression (approximately twofold) of wild-type DHH1 can cause reduced growth rates .

• Alternative P-body markers: Use independent P-body markers (e.g., SCD6-eYFP) when studying the effects of DHH1 mutants on P-body formation to distinguish between DHH1-specific effects and general P-body disruption .

• Stress response controls: Since environmental stress response (ESR) genes can be activated in DHH1 mutants , include controls to distinguish between direct effects of DHH1 mutation and secondary effects due to stress response activation.

• RNA binding and ATP hydrolysis assays: Include in vitro biochemical assays to confirm that mutations have the expected effects on DHH1's enzymatic activities.

What factors contribute to variability in DHH1 antibody performance across different experimental systems?

Several factors can impact DHH1 antibody performance across different experimental systems:

• Antibody source and specificity: Different epitopes recognized by various antibodies can affect recognition efficiency, especially if the epitope is near post-translational modification sites or interaction surfaces.

• Species cross-reactivity: While some DHH1 antibodies show reactivity with human, mouse, and rat samples , sequence variations between species may affect antibody binding efficiency.

• Cell fixation methods: For immunofluorescence applications, different fixation protocols (paraformaldehyde vs. methanol fixation) can affect epitope accessibility and antibody binding.

• Buffer conditions: The composition of lysis and immunoprecipitation buffers can significantly impact antibody performance, particularly when studying DHH1 in P-bodies, which are sensitive to buffer conditions .

• Protein expression levels: DHH1 expression levels vary between cell types and conditions, potentially affecting detection sensitivity.

• Post-translational modifications: These modifications may mask epitopes or alter protein conformation, affecting antibody recognition.

• Protein complexes: DHH1's incorporation into large RNP complexes may restrict antibody accessibility to certain epitopes.

How does DHH1's role in P-body formation relate to its function in regulating specific mRNAs?

DHH1's dual role in P-body formation and mRNA regulation represents an important area of ongoing research:

• Selective regulation: DHH1 and Pat1 collaboratively regulate specific transcripts rather than globally affecting all mRNAs. Transcripts showing concerted translational repression by Pat1/DHH1 often have specific characteristics .

• Developmental regulation: In trypanosomes, DHH1 selectively affects developmentally regulated mRNAs. Expression of DHH1 mutants stabilizes mRNAs normally downregulated in insect-form trypanosomes while accelerating the decline of mRNAs typically upregulated in insect-form trypanosomes .

• Aggregate formation: P-bodies contain numerous proteins with low-complexity sequences, similar to proteins highly represented in mammalian RNP granules . The Hsp40 chaperone Ydj1, which contains a low-complexity domain and controls prion protein aggregation, is required for the formation of DHH1-GFP foci upon glucose depletion .

• Degradation vs. storage: P-bodies may function both as sites of mRNA degradation and as storage compartments for translationally repressed mRNAs. The balance between these functions may depend on cellular conditions and the specific mRNAs involved.

• Biochemical properties: DHH1, ATP, and RNA are sufficient to form liquid droplets in vitro, suggesting that the biochemical properties of DHH1 directly contribute to phase separation phenomena underlying P-body formation .

What are the latest methodological advances for studying DHH1's interaction network?

Recent technological advances have expanded our ability to investigate DHH1's interaction network:

• Proximity-dependent biotin identification (BioID): This technique can identify proteins that transiently interact with DHH1 in living cells by fusing DHH1 to a biotin ligase.

• High-affinity antibody isolation: Using high-affinity antibodies to isolate core DHH1-GFP complexes at maximal yield under conditions that preserve the P-body aggregate state has revealed new classes of proteins that coenrich with DHH1 during P-body induction .

• Mass spectrometry: Proteomic analysis of DHH1 complexes has identified proteins involved in nucleotide or amino acid metabolism, glycolysis, transfer RNA aminoacylation, and protein folding as components of DHH1-containing complexes .

• CRISPR-Cas9 screening: Genome-wide screens can identify genes that, when disrupted, alter DHH1 localization or function.

• Live-cell imaging with single-molecule resolution: These techniques allow real-time tracking of DHH1 interactions with mRNAs and other proteins in living cells.

• Integrative omics approaches: Combining ribosome profiling, RNA-Seq, CAGE analysis of capped mRNAs, RNA Polymerase II ChIP-Seq, and TMT-mass spectrometry provides a comprehensive view of how DHH1 and its partners like Pat1 affect transcript abundance, translation, and protein production .